WO2002057453A3 - Polypeptides et acides nucleiques codant ces derniers - Google Patents

Polypeptides et acides nucleiques codant ces derniers Download PDF

Info

Publication number
WO2002057453A3
WO2002057453A3 PCT/US2001/050331 US0150331W WO02057453A3 WO 2002057453 A3 WO2002057453 A3 WO 2002057453A3 US 0150331 W US0150331 W US 0150331W WO 02057453 A3 WO02057453 A3 WO 02057453A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acids
polypetides
acids encoding
encoding same
disclosed
Prior art date
Application number
PCT/US2001/050331
Other languages
English (en)
Other versions
WO2002057453A2 (fr
Inventor
Esha A Gangolli
Meera Patturajan
Corine A M Vernet
Uriel M Malyankar
Ramesh Kekuda
David J Stone
David Anderson
Richard A Shimkets
Catherine E Burgess
Bryan D Zerhusen
Xiaohong Liu
Kimberly A Spytek
Stacie J Casman
Ferenc L Boldog
Glennda Smithson
Li Li
Weizhen Ji
Original Assignee
Curagen Corp
Esha A Gangolli
Meera Patturajan
Corine A M Vernet
Uriel M Malyankar
Ramesh Kekuda
David J Stone
David Anderson
Richard A Shimkets
Catherine E Burgess
Bryan D Zerhusen
Xiaohong Liu
Kimberly A Spytek
Stacie J Casman
Ferenc L Boldog
Glennda Smithson
Li Li
Weizhen Ji
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curagen Corp, Esha A Gangolli, Meera Patturajan, Corine A M Vernet, Uriel M Malyankar, Ramesh Kekuda, David J Stone, David Anderson, Richard A Shimkets, Catherine E Burgess, Bryan D Zerhusen, Xiaohong Liu, Kimberly A Spytek, Stacie J Casman, Ferenc L Boldog, Glennda Smithson, Li Li, Weizhen Ji filed Critical Curagen Corp
Priority to JP2002558505A priority Critical patent/JP2005508601A/ja
Priority to CA002433313A priority patent/CA2433313A1/fr
Priority to EP01993342A priority patent/EP1352065A2/fr
Publication of WO2002057453A2 publication Critical patent/WO2002057453A2/fr
Publication of WO2002057453A3 publication Critical patent/WO2002057453A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Abstract

L'invention concerne des séquences d'acides nucléiques qui codent de nouveaux polypeptides. L'invention concerne également des polypeptides codés par ces séquences d'acides nucléiques, ainsi que des anticorps qui se lient de manière immunospécifique au polypeptide. L'invention concerne également des dérivés, variants, mutants ou fragments dudit polypeptide, polynucléotide ou anticorps. L'invention concerne en outre des méthodes de traitement, de diagnostic et de recherche pour diagnostiquer, traiter et prévenir des troubles dans lesquels intervient un acide nucléique quelconque ou une protéine quelconque de ces nouveaux acides nucléiques et protéines humains.
PCT/US2001/050331 2000-12-19 2001-12-19 Polypeptides et acides nucleiques codant ces derniers WO2002057453A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002558505A JP2005508601A (ja) 2000-12-19 2001-12-19 ポリペプチドおよびそれをコードする核酸
CA002433313A CA2433313A1 (fr) 2000-12-19 2001-12-19 Polypeptides et acides nucleiques codant ces derniers
EP01993342A EP1352065A2 (fr) 2000-12-19 2001-12-19 Polypeptides et acides nucleiques codant ces derniers

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US26570400P 2000-12-19 2000-12-19
US60/256,704 2000-12-19
US25731400P 2000-12-20 2000-12-20
US60/257,314 2000-12-20
US28815301P 2001-05-02 2001-05-02
US60/288,153 2001-05-02
US29407501P 2001-05-29 2001-05-29
US60/294,075 2001-05-29
US30750601P 2001-07-24 2001-07-24
US60/307,506 2001-07-24
US31159001P 2001-08-10 2001-08-10
US31161301P 2001-08-10 2001-08-10
US60/311,590 2001-08-10
US60/311,613 2001-08-10
US31561701P 2001-08-29 2001-08-29
US60/315,617 2001-08-29
US32235801P 2001-09-14 2001-09-14
US60/322,358 2001-09-14

Publications (2)

Publication Number Publication Date
WO2002057453A2 WO2002057453A2 (fr) 2002-07-25
WO2002057453A3 true WO2002057453A3 (fr) 2003-08-14

Family

ID=27578753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/050331 WO2002057453A2 (fr) 2000-12-19 2001-12-19 Polypeptides et acides nucleiques codant ces derniers

Country Status (3)

Country Link
JP (1) JP2005508601A (fr)
CA (1) CA2433313A1 (fr)
WO (1) WO2002057453A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3016482A1 (fr) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research Nouvelle molecule immunoregulatrice b7-h1,
US7122345B2 (en) 2001-01-09 2006-10-17 Curagen Corporation Nucleic acid encoding a NOVX13 polypeptide
WO2003038094A1 (fr) * 2001-10-30 2003-05-08 Bayer Healthcare Ag Regulation du transporteur de glucose humain
AU2002357609A1 (en) * 2001-12-21 2003-07-09 Takeda Chemical Industries, Ltd. Novel proteins and dnas thereof
WO2004106935A2 (fr) * 2003-05-27 2004-12-09 Bayer Healthcare Ag Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 103 couples aux proteines g (gpr103)
EP1730189A2 (fr) * 2004-02-20 2006-12-13 DeveloGen Aktiengesellschaft Utilisation de produits de proteines secretees pour la prevention et le traitement de maladies du pancreas et/ou de l'obesite, et/ou du syndrome metabolique
JP5303146B2 (ja) 2004-10-06 2013-10-02 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Ｂ７−ｈ１ならびに癌の診断、予後診断および処置の方法
WO2006055704A2 (fr) * 2004-11-17 2006-05-26 Curagen Corporation Anticorps diriges contre des proteines ten-m et utilisations associees
JPWO2006062135A1 (ja) * 2004-12-07 2008-06-12 独立行政法人理化学研究所 精神疾患の診断薬
US8642280B2 (en) 2008-11-07 2014-02-04 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
ES2714708T3 (es) 2013-10-01 2019-05-29 Mayo Found Medical Education & Res Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
WO2015179654A1 (fr) 2014-05-22 2015-11-26 Mayo Foundation For Medical Education And Research Distinction d'anticorps anti-b7-h1 agonistes et antagonistes
US10517875B2 (en) 2014-07-23 2019-12-31 Mayo Foundation for Medical Engineering and Research Targeting DNA-PKcs and B7-H1 to treat cancer
WO2017075045A2 (fr) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Anticorps anti-b7-h1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066690A2 (fr) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Nouveaux composes
WO2001072961A2 (fr) * 2000-03-24 2001-10-04 Smithkline Beecham Corporation Nouveaux composes
WO2002046409A2 (fr) * 2000-12-06 2002-06-13 Curagen Corporation Proteines et acides nucleiques les codant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066690A2 (fr) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Nouveaux composes
WO2001072961A2 (fr) * 2000-03-24 2001-10-04 Smithkline Beecham Corporation Nouveaux composes
WO2002046409A2 (fr) * 2000-12-06 2002-06-13 Curagen Corporation Proteines et acides nucleiques les codant

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 1 October 2000 (2000-10-01), XP002223479, retrieved from EMBL Database accession no. Q9NQ36 *
GRIMMOND SEAN ET AL: "Cloning, mapping, and expression analysis of a gene encoding a novel mammalian EGF-related protein (SCUBE1).", GENOMICS, vol. 70, no. 1, 15 November 2000 (2000-11-15), pages 74 - 81, XP002223477, ISSN: 0888-7543 *
GRIMMOND SEAN ET AL: "Expression of a novel mammalian epidermal growth factor-related gene during mouse neural development.", MECHANISMS OF DEVELOPMENT, vol. 102, no. 1-2, April 2001 (2001-04-01), pages 209 - 211, XP002223478, ISSN: 0925-4773 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9370565B2 (en) 2000-04-28 2016-06-21 The Johns Hopkins University Dendritic cell co-stimulatory molecules
US8124617B2 (en) 2005-09-01 2012-02-28 Takeda San Diego, Inc. Imidazopyridine compounds
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
US8008332B2 (en) 2006-05-31 2011-08-30 Takeda San Diego, Inc. Substituted indazoles as glucokinase activators
US8394843B2 (en) 2006-05-31 2013-03-12 Takeda California, Inc. Substituted isoindoles as glucokinase activators
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
US8173645B2 (en) 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators

Also Published As

Publication number Publication date
CA2433313A1 (fr) 2002-07-25
WO2002057453A2 (fr) 2002-07-25
JP2005508601A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
WO2002014368A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2002006339A3 (fr) Nouvelles proteines et acides nucleiques les codant
WO2002055705A3 (fr) Proteines et acides nucleiques codant ces proteines
WO2002064791A3 (fr) Proteines et acides nucleiques codant celles-ci
WO2002050277A3 (fr) Proteines et acides nucleiques codant pour celles-ci
WO2002057453A3 (fr) Polypeptides et acides nucleiques codant ces derniers
WO2002068649A3 (fr) Proteines et acides nucleiques les codant
WO2002057450A3 (fr) Proteines et acides nucleiques les codant
WO2002081518A3 (fr) Proteines, polynucleotides les codant et leurs procedes d'utilisation
WO2001090155A3 (fr) Nouvelles proteines et acides nucleiques codant pour ces proteines
WO2002029058A3 (fr) Nouvelles proteines humaines, polynucleotides codant pour ces proteines et methodes d'utilisation associees
WO2002098917A3 (fr) Proteines, polynucleotides codant pour lesdites proteines et methodes d'utilisation desdites proteines
WO2001081578A3 (fr) Nouvelles proteines et acides nucleiques codant ces dernieres
WO2004015060A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et methodes d'utilisation associees
WO2002016599A3 (fr) Nouvelles proteines et acides nucleiques les codant
WO2002068652A3 (fr) Proteines et acides nucleiques codant ces proteines
WO2002029038A3 (fr) Nouvelles proteines, acides nucleiques codant ces derniers et anticorps diriges contre ces proteines
WO2002055704A3 (fr) Proteines, polynucleotides codant pour elles et procedes d'utilisation correspondants
WO2002010216A3 (fr) Nouvelles proteines et acides nucleiques codant pour elles
WO2002055702A3 (fr) Protéines humaines, polynucléotides les codant et procédés d'utilisation correspondants
WO2002081510A3 (fr) Proteines, polynucleotides codant pour celles-ci et methodes d'utilisation
WO2002046229A3 (fr) Nouvelles proteines et acides nucleiques codant celles-ci
WO2001066747A3 (fr) Nouvelles proteines et acides nucleiques codant lesdites proteines
WO2002066643A3 (fr) Proteines, polynucleotides codant pour ces proteines et procedes d'utilisation
WO2002099116A3 (fr) Polypeptides therapeutiques, acides nucleiques codant ces polypeptides et procedes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2433313

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002558505

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001993342

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002245183

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001993342

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001993342

Country of ref document: EP